Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ]: Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ]: Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ]: Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ]: Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ]: Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010

Apricus Biosciences to Present at the PrecisionIR Informed Investors Forum Biotech, Healthcare and Pharma Virtual Conference on

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. healthcare-and-pharma-virtual-conference-on.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SAN DIEGO--([ BUSINESS WIRE ])--Apricus Biosciences (aApricus Bioa) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at PrecisionIR's Informed Investors Forum Biotech, Healthcare and Pharma Virtual Conference on October 13, 2010 at 12:00pm Eastern time. Interested parties can access the audio webcast with slide presentation at [ http://www.vcall.com/customevent/conferences/biotech/20101013/index.html ].

About Apricus Biosciences

Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit [ http://www.apricusbio.com ].